Passage BIO, Inc. (PASG): Total Assets
$62.28M
As of 2025-12-31
$25.18M
As of 2026-06-30
-36.5%
3-year compound annual growth
-28.3%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $62.28M | -39.2% | 2026-03-03, Balance as of period end |
| 2024-12-31 | $102.41M | -32.0% | 2026-03-03, Balance as of period end |
| 2023-12-31 | $150.54M | -38.2% | 2025-03-04, Balance as of period end |
| 2022-12-31 | $243.55M | -31.4% | 2024-03-04, Balance as of period end |
| 2021-12-31 | $355.08M | +8.3% | 2023-03-06, Balance as of period end |
| 2020-12-31 | $328.01M | +83.6% | 2022-03-03, Balance as of period end |
| 2019-12-31 | $178.61M | n/a | 2021-03-03, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Passage BIO, Inc. (PASG) | 2025-12-31 | $62.28M | -39.2% |
| Elutia Inc. (ELUT) | 2025-12-31 | $62.35M | +72.6% |
| Cardiff Oncology, Inc. (CRDF) | 2025-12-31 | $61.88M | -36.3% |
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | $59.74M | -41.2% |
| Fennec Pharmaceuticals Inc. (FENC) | 2025-12-31 | $70.55M | +57.0% |
| Senti Biosciences Holdings, Inc. (SNTI) | 2025-12-31 | $51.22M | -47.6% |
| Armata Pharmaceuticals, Inc. (ARMP) | 2025-12-31 | $76.88M | -11.1% |
| Alpha Cognition Inc. (ACOG) | 2025-12-31 | $79.73M | +57.1% |
| Cognition Therapeutics Inc (CGTX) | 2025-12-31 | $48.39M | +60.1% |
Compare PASG, ELUT, CRDF, SGMOQ side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗